What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question

A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Basile, Vittoria, Puglisi, Soraya, Altieri, Barbara, Canu, Letizia, Libè, Rossella, Ceccato, Filippo, Beuschlein, Felix, Quinkler, Marcus, Calabrese, Anna, Perotti, Paola, Berchialla, Paola, Dischinger, Ulrich, Megerle, Felix, Baudin, Eric, Bourdeau, Isabelle, Lacroix, André, Loli, Paola, Berruti, Alfredo, Kastelan, Darko, Haak, Harm R., Fassnacht, Martin, Terzolo, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066814/
https://www.ncbi.nlm.nih.gov/pubmed/33916613
http://dx.doi.org/10.3390/jpm11040269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066814/
https://www.ncbi.nlm.nih.gov/pubmed/33916613
http://dx.doi.org/10.3390/jpm11040269

Ejemplares similares